Board of Directors
Arthur Kuan - Chief Executive Officer
Arthur currently serves as Chief Executive Officer and Director on the Board at Cold Genesys, a privately-held, clinical-stage biopharmaceutical company focused on the research, acquisition and development of novel immunotherapies, including an oncolytic virus for the treatment of bladder cancer and a variety of other solid tumor types. Arthur is a Founding Member of Ally Bridge Group, a global healthcare-focused investment platform, and plays an active role in managing the fund’s portfolio companies. Previously, Arthur was a member of Themes Investment Partners, a Private Equity fund based in Hong Kong, where he played a central role in coordinating cross-border technology transfer and regulatory submissions for portfolio companies. He began his career in an operational role at Dinova Capital, a Shanghai-based, medical technology incubator fund, evaluating medical device investment opportunities. Arthur received his M.S. in Biotechnology from the Johns Hopkins University and his B.A. in Biology from the University of Pennsylvania.
Luke Li, M.D. - Managing Director, Ally Bridge Group
Luke has 30 years of experience in biopharma and healthcare business. Currently, he is a Managing Director at Ally Bridge Group (“ABG”), a global healthcare investment platform, where he oversees biopharma investment opportunities for the healthcare fund and plays an important role in guiding science and business development for ABG’s portfolio companies. Before joining ABG, Luke was an Executive Director and the Head of Global Biotherapeutics, External R&D Innovation at Pfizer from 2010 to 2015, where he led search and evaluation as well as business development for in-licensing of innovative assets and cutting-edge technologies. He focused on Oncology, Biotechnologies, Pharmaceutical Sciences as well as Biosimilars to strengthen Pfizer’s pipeline. Luke served as Amgen’s Executive Director from 1993 to 2009, leading discovery research to IND, in which he advanced more than 3 dozen biologics into development, including several marketed products. From 1986 to 1992, Luke completed his fellowship training in Hematology/Oncology, and then became an Assistant Professor in Medicine at Washington University Medical School. Luke earned his M.D. from Fujian Medical University.
Ronald Cheng - Managing Director, Wellchamp Capital
Ronald has more than 20 years of experience in the Finance and Investment realm with an emphasis in media and biotechnology. He is the Founder and Managing Director at Wellchamp Capital Limited, a Hong Kong SFC registered asset management and investment advisory firm. In 2002, Ronald was Investor and Director of Plasmagene Bioscience, a biotechnology company founded by Dr. Alex Yeung, which eventually became listed as a part of the Hong Kong Stock Exchange (SEHK). Ronald was also Investor and Director of New Media Corp, a telecommunications media company invested in news and publication since 1975. Ronald holds a B.S. from The Chinese University of Hong Kong in Business Administration.
Simone Song - Senior Partner, ORI Capital
Simone is Founder and Senior Partner of ORI Capital. She was the former Head of Goldman Sachs Healthcare Investment Banking for Greater China. Simone has more than 25 years of experience in healthcare sector. Prior to joining Goldman Sachs, she was a Managing Director of Cowen Group, a member of the advisory board of AXA Investment Managers, and an executive board advisor to AXA Asia Pacific Holdings. Simone holds a B.A. in Economics from Fudan University in China and an M.A. in Economics from Claremont Graduate School in the United States.
Jim Mulé, Ph.D.
Jim is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center, Tampa, Florida. He is recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. He has published nearly 200 articles. Jim serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, among others). Jim remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI. He was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director’s Board of Scientific Counselors (BSC-A). Jim also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Jim received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal postgraduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Jim moved to Palo Alto, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endowed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.